Profile
Senthil Sundaram held several positions in the pharmaceutical industry, including Chief Executive Officer & Director at Terns Pharmaceuticals, Inc., Vice President & Head-Business Development at Intercept Pharmaceuticals, Inc., and CFO & Principal Accounting Officer at Nightstar Therapeutics Ltd.
He also served as an Independent Director at Sio Gene Therapies, Inc. and Social Capital Suvretta Holdings Corp.
I.
Sundaram received his undergraduate degree from Brown University.
Former positions of Senthil Sundaram
| Companies | Position | End |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Chief Executive Officer | 03/08/2023 |
| SIO GENE THERAPIES INC. | Director/Board Member | 05/04/2023 |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Director/Board Member | 07/06/2019 |
| NIGHTSTAR THERAPEUTICS PLC | Director of Finance/CFO | 07/06/2019 |
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2017 |
Training of Senthil Sundaram
| Brown University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Social Capital Suvretta Holdings Corp. I
 Social Capital Suvretta Holdings Corp. I Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. I is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on the search for target business operating in the biotechnology industry and within the neurology subsector. The company was founded by Chamath Palihapitiya and Kishen C. Mehta on February 25, 2021 and is headquartered in Henderson, NV. | Finance |
- Stock Market
- Insiders
- Senthil Sundaram
